Latest Decheng Capital LLC Stock Portfolio
$661Million | No. of Holdings #14
Decheng Capital LLC Performance
2026 Q1-6.14%
YTD-6.14%
2025+68.98%
About Decheng Capital LLC and 13F Hedge Fund Stock Holdings
On 2026-05-13, the fund reported it's updated stock portfolio. In the 13F Holdings report, Decheng Capital LLC reported an equity portfolio of $661.3 Millions as of 31 Mar, 2026. <br><br> The top stock holdings of Decheng Capital LLC are , NUVB, . The fund has invested 65.2% of it's portfolio in CG ONCOLOGY INC and 16.8% of portfolio in NUVATION BIO INC. <br><br> The fund managers got completely rid off CRINETICS PHARMACEUTICALS IN (CRNX), AURA BIOSCIENCES, INC. (AURA) and 4D MOLECULAR THERAPEUTICS IN (FDMT) stocks. They significantly reduced their stock positions in KRYSTAL BIOTECH INC (KRYS), REVOLUTION MEDICINES INC(NSM) (RVMD) and NEWAMSTERDAM PHARMA CO NV (NAMS).
Decheng Capital LLC Equity Portfolio Value
Last Reported on: 13 May, 2026
$661Million
as of May 13, 2026Decheng Capital LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Decheng Capital LLC made a return of -6.14% in the last quarter. In trailing 12 months, it's portfolio return was 107.98%.
- Performance
- S&P 500
New Buys
No new stocks were added by Decheng Capital LLC
Additions
No additions were made to existing positions by Decheng Capital LLC
Reductions
| Ticker | % Reduced |
|---|---|
| krystal biotech inc | -57.8 |
| revolution medicines inc(nsm) | -53.25 |
| newamsterdam pharma co nv | -45.1 |
| upstream bio inc. | -13.31 |
| arcus biosciences, inc | -11.77 |
Decheng Capital LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| nuvation bio inc. | -213,198 |
| aura biosciences, inc. | -1,964,630 |
| crinetics pharmaceuticals in | -4,315,180 |
| rezolute inc | -141,364 |
| 4d molecular therapeutics in | -332,333 |
Decheng Capital LLC got rid off the above stocks
Sector Distribution
Decheng Capital LLC has about 73.7% of it's holdings in Others sector.
- Others
- Healthcare
| Sector | % |
|---|---|
| Others | 73.7 |
| Healthcare | 26.3 |
Market Cap. Distribution
Decheng Capital LLC has about 1.4% of it's portfolio invested in the large-cap and mega-cap stocks.
- UNALLOCATED
- SMALL-CAP
- MICRO-CAP
- MID-CAP
- LARGE-CAP
| Category | % |
|---|---|
| UNALLOCATED | 73.7 |
| SMALL-CAP | 21.2 |
| MICRO-CAP | 1.9 |
| MID-CAP | 1.8 |
| LARGE-CAP | 1.4 |
Stocks belong to which Index?
About 24.9% of the stocks held by Decheng Capital LLC either belong to S&P 500 or RUSSELL 2000 index.
- Others
- RUSSELL 2000
| Index | % |
|---|---|
| Others | 75.1 |
| RUSSELL 2000 | 24.9 |
Decheng Capital LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Decheng Capital LLC
Decheng Capital LLC has 14 stocks in it's portfolio. About 98.2% of the portfolio is in top 10 stocks. NUVB proved to be the most loss making stock for the portfolio. was the most profitable stock for Decheng Capital LLC last quarter.
$661.32MTotal Value
19.00Positions
13 May, 2026Last Reported
| Expand | Holdingsorted ascending | % Portfolio | Shares Held | $ Value | % Change |
|---|---|---|---|---|---|
 Aclaris Therapeutics, Inc. Decheng Capital LLC's holding in Aclaris Therapeutics, Inc. over time | 2.29% | 4,041,740 | $15.16M 2.29% | 0%unchanged 0 percentunchanged | |
 Aura Biosciences, Inc. Decheng Capital LLC's holding in Aura Biosciences, Inc. over time | 0% | 0.00 | $0.00 0% | 100%decreased 100 percentsold off | |
 BYSI Beyondspring Inc.Beyondspring Inc.BYSI | 0.94% | 3,800,700 | $6.23M 0.94% | 0%unchanged 0 percentunchanged | |
 Crinetics Pharmaceuticals In Decheng Capital LLC's holding in Crinetics Pharmaceuticals In over time | 0% | 0.00 | $0.00 0% | 100%decreased 100 percentsold off | |
 Equillium Inc. Decheng Capital LLC's holding in Equillium Inc. over time | 1.34% | 4,447,310 | $8.89M 1.34% | 0%unchanged 0 percentunchanged | |
 4d Molecular Therapeutics In Decheng Capital LLC's holding in 4d Molecular Therapeutics In over time | 0% | 0.00 | $0.00 0% | 100%decreased 100 percentsold off | |
 Krystal Biotech Inc Decheng Capital LLC's holding in Krystal Biotech Inc over time | 0.28% | 7,300 | $1.89M 0.28% | 57.8%decreased 57.8 percentreduced | |
 Lyell Immunopharma, Inc. Decheng Capital LLC's holding in Lyell Immunopharma, Inc. over time | 2.1% | 692,050 | $13.88M 2.1% | 0%unchanged 0 percentunchanged | |
 NAMS Newamsterdam Pharma Co NvNewamsterdam Pharma Co NvNAMS | 1.57% | 325,057 | $10.41M 1.57% | 45.1%decreased 45.1 percentreduced | |
 Nuvation Bio Inc. Decheng Capital LLC's holding in Nuvation Bio Inc. over time | 16.84% | 25,954,400 | $111.34M 16.84% | 0%unchanged 0 percentunchanged | |
Nuvation Bio Inc. Decheng Capital LLC's holding in Nuvation Bio Inc. over time | 0% | 0.00 | $0.00 0% | 100%decreased 100 percentsold off | |
 Pyxis Oncology, Inc (Formerly Apexigen) Decheng Capital LLC's holding in Pyxis Oncology, Inc (Formerly Apexigen) over time | 0.07% | 326,810 | $477.1K 0.07% | 0%unchanged 0 percentunchanged | |
 Arcus Biosciences, Inc Decheng Capital LLC's holding in Arcus Biosciences, Inc over time | 1.56% | 477,819 | $10.32M 1.56% | 11.77%decreased 11.77 percentreduced | |
 Revolution Medicines Inc(Nsm) Decheng Capital LLC's holding in Revolution Medicines Inc(Nsm) over time | 1.38% | 93,500 | $9.09M 1.38% | 53.25%decreased 53.25 percentreduced | |
 Rezolute Inc Rezolute IncRZLT Decheng Capital LLC's holding in Rezolute Inc over time | 0% | 0.00 | $0.00 0% | 100%decreased 100 percentsold off | |
 Zentalis Pharmaceuticals Inc. Decheng Capital LLC's holding in Zentalis Pharmaceuticals Inc. over time | 0.47% | 1,323,330 | $3.10M 0.47% | 0%unchanged 0 percentunchanged | |
Com Cg Oncology IncCg Oncology Inc | 65.21% | 6,371,670 | $431.24M 65.21% | 0%unchanged 0 percentunchanged | |
Com Upstream Bio Inc.Upstream Bio Inc. | 3.71% | 2,724,870 | $24.52M 3.71% | 13.31%decreased 13.31 percentreduced | |
Com Aardvark Therapeutics IncAardvark Therapeutics Inc | 2.23% | 3,917,300 | $14.77M 2.23% | 0%unchanged 0 percentunchanged | |